Methods of treating a meiotic kinesin-associated disease
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12Q-001/68
G01N-033/50
A61K-031/7088
A61K-031/7105
G01N-033/574
C12N-005/00
출원번호
US-0591678
(2015-01-07)
등록번호
US-9645136
(2017-05-09)
발명자
/ 주소
Pellman, David
출원인 / 주소
DANA-FARBER CANCER INSTITUTE, INC.
대리인 / 주소
Brinks Gilson & Lione
인용정보
피인용 횟수 :
0인용 특허 :
20
초록▼
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the gro
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provided.
대표청구항▼
1. A method for identifying a compound that inhibits activity of meiotic kinesin HSET, the method comprising: (a) providing an indicator composition comprising: a sample from a tumor, wherein at least 50% of tumor cells comprise supernumerary centrosomes, andthe meiotic kinesin HSET;(b) contacting t
1. A method for identifying a compound that inhibits activity of meiotic kinesin HSET, the method comprising: (a) providing an indicator composition comprising: a sample from a tumor, wherein at least 50% of tumor cells comprise supernumerary centrosomes, andthe meiotic kinesin HSET;(b) contacting the indicator composition with a test compound; and(c) determining activity of the meiotic kinesin HSET in the presence of the test compound, wherein reduction of activity of the meiotic kinesin HSET in the presence of the test compound, as compared to activity of the meiotic kinesin HSET in the absence of the test compound identifies the test compound as the compound that inhibits the activity of a meiotic kinesin HSET,wherein the compound that inhibits activity of meiotic kinesis HSET, when administered to the sample, inhibits the meiotic kinesis HSET causing: disruption of the clustering of extra centrosomes in the at least 50% of the tumor cells comprising supernumerary centrosomes, andpromotion of multipolar mitoses to selectively induce cell death of the at least 50% of the tumor cells comprising supernumerary centrosomes;wherein the determining activity comprises measuring at least one of HSET mRNA, HSET protein expression levels, one or more enzymatic activities or biological activities of HSET, HSET ATPase activity, microtubule binding activity and centrosome clustering activity, or a combination thereof. 2. The method of claim 1, wherein the indicator composition is contacted with each member of a library of test compounds and one or more test compounds within the library are selected that inhibit the activity if the meiotic kinesin HSET. 3. The method of claim 1, wherein the compound that inhibits activity of meiotic kinesin HSET is selected from a kinesin-14 family member. 4. The method of claim 1, wherein the compound that inhibits activity of meiotic kinesin HSET is selected from the groups consisting of RNAi agent, an antisense agent, and a small molecule. 5. The method of claim 1, wherein the test compound that inhibits activity of meiotic kinesin HSET, upon administration of the compound to a subject with a tumor, wherein at least 50% of tumor cells comprise supernumerary centrosomes, is capable of causing (a) disruption of the clustering of extra centrosomes in the at least 50% of tumor cells comprising supernumerary centrosomes, and(b) promotion of multipolar mitoses to selectively induce cell death of the at least 50% of tumor cells comprising supernumerary centrosomes. 6. The method of claim 1, wherein the indicator composition is a cell that expresses HSET. 7. The method of claim 6, wherein the cell that expresses HSET is a cell that naturally expresses HSET. 8. The method of claim 7, wherein the cell that expresses HSET is selected from the group consisting of MDA-231, MMEDX 4N and N1E-115. 9. The method of claim 6, wherein the cell that expresses HSET is a cell engineered to express or overexpress HSET. 10. The method of claim 1, wherein the indicator composition is a cell-free composition that comprises HSET.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (20)
Finer, Jeffrey T.; Malik, Fady; Sakowicz, Roman; Shumate, Christopher; Wood, Kenneth, Compositions and assays utilizing ADP or phosphate for detecting protein modulators.
Jeffrey T. Finer ; Fady Malik ; Roman Sakowicz ; Christopher Shumate ; Kenneth Wood, Compositions and assays utilizing ADP or phosphate for detecting protein modulators.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.